ProLynx Announces Active IND of a Novel Ultra-Long Acting PEG–SN-38 Conjugate to Treat Solid Tumors
June 02, 2015 14:05 ET
|
ProLynx LLC
SAN FRANCISCO, June 02, 2015 (GLOBE NEWSWIRE) -- ProLynx LLC announced today that an Investigational New Drug (IND) application for their novel, ultra-long acting PEG~SN-38 (PLX-0264; DFP-13318)...